8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 3, 2014

Shire plc

_________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands

_________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630                                                  98-0601486

(Commission File Number)                (IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin

24, Republic of Ireland

_________________________________________________________________________

(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               +353 1 429 7700

_________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.   Other Events

Shire plc has issued the press releases attached hereto as Exhibits 99.1, 99.2 and 99.3 which are incorporated by reference herein.

Item 9.01.   Financial Statements and Exhibits

(d)  Exhibits.  The following exhibits are filed herewith:

99.1           Press Release dated March 3, 2014

99.2           Press Release dated March 3, 2014

99.3           Press Release dated March 3, 2014

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/ Tatjana May
	Name:	Tatjana May

Dated: March 3, 2014

EXHIBIT INDEX
Number	Description
99.1	Press release dated March 3, 2014
99.2	Press release dated March 3, 2014
99.3	Press release dated March 3, 2014

EX-99.1

Exhibit 99.1

Press Release
www.shire.com

Total Voting Rights

March 3, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with the Financial Conduct Authority's (the “FCA”) Disclosure and Transparency Rule 5.6.1R, notifies the market of the following:

At close of business on February 28, 2014, the Company’s issued ordinary share capital comprised 587,949,918 ordinary shares of 5 pence each with voting rights and a further 9,823,536 ordinary shares held in treasury.

Therefore the total number of voting rights in the Company is 587,949,918. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Tony Guthrie

Deputy Company Secretary

For further information please contact:

Investor Relations
Laurie Stelzer	lstelzer@shire.com	+1 781 482 0733
Eric Rojas	erojas@shire.com	+1 781 482 0999
Sarah Elton-Farr	seltonfarr@shire.com	+44 1256 894157

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

www.shire.com

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

EX-99.2

Exhibit 99.2

Press Release
www.shire.com

Director/PDMR Shareholding

March 3, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that on February 28, 2014, Stock Appreciation Rights (“SARs”) and Performance Share Awards (“PSAs”) were granted to Persons Discharging Managerial Responsibility (“PDMRs”) under Part A and Part B respectively of The Shire Portfolio Share Plan (“PSP”). SARs and PSAs will normally vest after three years, subject to any performance conditions being satisfied, with no consideration payable on these awards. The awards were granted over notional Ordinary Shares (“Shares”) and American Depositary Shares (“ADSs”) in the Company as follows:

PDMR	Type of Award(1)	Type of Security(2)	Number of Securities	Exercise Price
Flemming Ornskov	SAR	ADS	34,174	$168.54
	PSA	ADS	25,631	Nil
Tatjana May	SAR	Share	26,718	£33.83
	PSA	Share	22,329	Nil

(1)   SARs and PSAs granted to Dr. Ornskov and PSAs granted to Ms. May are subject to performance conditions.

(2)   One ADS is equal to three Shares.

The Company alsoannounces that PSAs granted to PDMRs on February 28, 2011 under Part B of the PSP vested on February 28, 2014. The number of Shares released and the number of Shares sold to satisfy personal tax liabilities were as follows:

PDMR	Shares Released(3)	Shares Sold(4)
Graham Hetherington(5)	61,689	29,287
Tatjana May	20,742	9,848

(3)   In accordance with the PSP rules, the vested PSAs have been increased to reflect the dividends paid by the Company during the period from the date of grant to the date of vesting.

(4)   Shares were sold on the London Stock Exchange at an average sale price of £33.98 each.

(5)   The PSA granted to Graham Hetherington was subject to performance conditions measured over the performance period 2011 to 2013. Based on the performance conditions, 100% of the PSA vested.

This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie

Deputy Company Secretary

For further information please contact:

Investor Relations
Laurie Stelzer	lstelzer@shire.com	+1 781 482 0733
Eric Rojas	erojas@shire.com	+1 781 482 0999
Sarah Elton-Farr	seltonfarr@shire.com	+44 1256 894157

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

www.shire.com

2

EX-99.3

Exhibit 99.3

Press Release
www.shire.com

Elections for Interim Dividend in Respect of the Six Months to December 31, 2013

March 3, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) announced on February 13, 2014 an interim dividend of 16.93 US cents per Ordinary Share payable on April 8, 2014 to shareholders on the register of members at the close of business on March 7, 2014.

Shareholders are reminded that the final date for submission of elections to receive UK sourced dividends via the income access share arrangements is March 7, 2014.

In the absence of any such elections, previous elections or deemed elections will remain in force.

Shareholders who do not elect (or have not been deemed to elect) to receive UK sourced dividends through the income access share arrangements are reminded that their dividends will be Irish sourced and subject to Irish dividend withholding tax unless the Company's Registrar is in possession of a valid exemption form by 5pm on March 7, 2014.  Exemption forms may be submitted by email to queriesdividendplanning@equiniti.com

Enquiries may be addressed to the Company’s Registrar’s Dividend Planning Team on + 44 (0) 1903 854 103.

Tony Guthrie

Deputy Company Secretary

For further information please contact:

Investor Relations
Laurie Stelzer	lstelzer@shire.com	+1 781 482 0733
Eric Rojas	erojas@shire.com	+1 781 482 0999
Sarah Elton-Farr	seltonfarr@shire.com	+44 1256 894157

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

www.shire.com

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX